Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date Sort descending | Expire Date | Purpose |
|---|---|---|---|---|---|
| Notice of Special Interest (NOSI): IDEA2Health: Innovative Data Evaluation and Analysis to Health | NOT-HL-22-001 | NHLBI | The purpose of this Notice of Special Interest (NOSI) is to inform applicants to the National Heart, Lung, and Blood Institute (NHLBI) of an area of special interest in the development and… More | ||
| Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional) | PAR-22-053 | NINDS | Functional Neurological Disorders (FNDs) are characterized by symptoms of altered voluntary motor or sensory function with clinical findings providing evidence of incompatibility between the symptoms… More | ||
| Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed) | PAR-22-061 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibit or enhance anti-tumor immune responses, and to… More | ||
| Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed) | PAR-22-062 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory/development basic research projects that elucidate mechanisms by which the human microbiome inhibit or enhance… More | ||
| Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional) | PAR-22-030 | NINDS | The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or… More | ||
| Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional) | PAR-21-355 | NICHD | This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through… More | ||
| Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed) | PAR-22-028 | NINDS | The purpose of this FOA is to provide investigators with a mechanism to access contract research/medical organizations (CROs/CMOs) and subject matter experts (SMEs) within the NINDS Ultra-Rare Gene-… More | ||
| Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional) | PAR-21-353 | NICHD | This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through… More | ||
| Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R03 - Clinical Trial Optional) | PAR-21-354 | NICHD | This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through… More | ||
| Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) | PAR-22-047 | NIA | The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug… More |